INTERNATIONAL JOURNAL OF CANCER, published by Wiley, stands as a premier platform for the dissemination of cutting-edge research in the fields of cancer research and oncology. With an impressive impact factor reflecting its rigorous peer-review process and significant contribution to the scientific community, this journal is categorized in Q1 for both Cancer Research and Oncology as of 2023. It boasts notable rankings, being placed 38th among 404 journals in Medicine - Oncology and 32nd among 230 in Biochemistry, Genetics, and Molecular Biology - Cancer Research, positioning it within the 90th and 86th percentiles, respectively. Since its inception in 1966 and continuing to 2024, the journal has played a pivotal role in advancing our understanding of cancer biology, treatment modalities, and innovative therapeutic approaches. While it operates under a subscription model, the journal is committed to making valuable research accessible to a broader scientific audience. Researchers, professionals, and students alike will find the INTERNATIONAL JOURNAL OF CANCER an essential resource for staying abreast of the latest advancements in cancer science.

Brain Tumor Pathology is a pivotal peer-reviewed journal published by SPRINGER JAPAN KK, focusing on the intricate and evolving field of brain tumor research. Established in 1997, the journal serves as a crucial platform for disseminating research findings, clinical studies, and reviews that advance our understanding of brain tumors and their pathology. With a notable impact factor, it ranks in the Q2 and Q3 quartiles in multiple categories, including Cancer Research, Medicine (miscellaneous), Neurology (clinical), and Oncology, reflecting its significance in enhancing scientific discourse and clinical practice. The journal is indexed by major databases, making it accessible to a wide audience of researchers, clinicians, and students who are dedicated to unraveling the complex mechanisms of brain tumors. Although it does not currently offer open access, its comprehensive articles and studies contribute to the vital conversation on brain tumor pathologies, treatment prospects, and innovation in the field. Researchers and professionals alike will find the insights and advancements presented in Brain Tumor Pathology indispensable for guiding future studies and improving clinical outcomes.

Journal of Bone Oncology, published by ELSEVIER, is a pivotal open access journal that has been advancing the field of oncology since its inception in 2012. Focused on the intricate relationship between bone-related malignancies and therapeutic advancements, this journal addresses critical issues in bone oncology, including novel treatments, diagnostic methodologies, and translational research. With a commendable impact factor reflecting its scholarly contributions and ranking in the Q2 category of oncology journals (2023), the Journal of Bone Oncology is recognized within the top 67th percentile across Scopus rankings, showcasing its relevance and quality in the medical oncology landscape. Available in open access, the journal promotes widespread dissemination of knowledge, ensuring that researchers, professionals, and students can access groundbreaking research that informs clinical practices and enhances patient outcomes. Located in Germany and targeting a global audience, the journal’s wealth of resources serves as an essential platform for fostering collaboration and innovation in the oncology community.

CANCER, published by Wiley, stands as a pivotal journal in the field of oncology and cancer research, boasting an impressive impact factor and consistently dynamic growth since its inception in 1948. With an ISSN of 0008-543X and an E-ISSN of 1097-0142, this esteemed journal is recognized for its rigorous peer-reviewed articles, making significant contributions to the understanding of cancer biology, treatment modalities, and clinical practices. CANCER holds a distinguished position in the academic community, securing its placement in the Q1 category for both cancer research and oncology, and ranks within the top percentiles on Scopus, indicating its high impact and relevance. The journal is particularly beneficial for researchers, professionals, and students seeking to stay abreast of the latest advancements in cancer science. By addressing essential research questions and providing pathways for new therapies, CANCER continues to play a crucial role in shaping the future of oncology and improving patient outcomes.

Neuro-Oncology Practice is a leading journal in the interdisciplinary field of neuro-oncology, published by Oxford University Press. With an ISSN of 2054-2577 and E-ISSN 2054-2585, this journal provides a critical platform for the dissemination of cutting-edge research and clinical advancements since its inception in 2014. As of 2023, it has achieved a Q2 ranking in Medicine (Miscellaneous), Neurology, and Oncology categories, reflecting its esteemed position in the academic community with impressive Scopus rankings, including a 74th percentile in the field of Medicine. Despite its non-open access status, Neuro-Oncology Practice aims to bridge the gap between laboratory research and clinical practice, offering valuable insights for professionals involved in the treatment and study of neurological cancers. The journal actively encourages submissions that explore innovative treatment strategies, enhance patient care, and advance our understanding of the complexities surrounding brain tumors. With a convergence period extending to 2024, it remains a crucial resource for researchers, practitioners, and students who are committed to improving outcomes in the field of neuro-oncology.

Neuro-Oncology Advances, published by Oxford University Press, is an esteemed open-access journal dedicated to advancing the field of neuro-oncology. Established in 2019, the journal has quickly gained recognition for its commitment to disseminating high-quality research, evidenced by its impressive Q1 rankings in Neurology (Clinical), Oncology, and Surgery categories as of 2023. With a rigorous peer-review process and a focus on innovative findings, Neuro-Oncology Advances serves as a vital platform for researchers, practitioners, and students seeking to stay at the forefront of developments in the diagnosis and treatment of nervous system tumors. The journal is accessible globally, ensuring that critical knowledge is available to help improve clinical outcomes and foster collaboration within this crucial interdisciplinary field.

Advances in Cancer Biology-Metastasis is an emerging journal published by Elsevier, aimed at advancing our understanding of the complexities of cancer biology, with a specific focus on the mechanisms and pathways related to metastasis. With an E-ISSN of 2667-3940, this journal offers a platform for researchers, professionals, and students in the fields of Cancer Research and Cell Biology to disseminate innovative findings and discuss novel therapeutic approaches. Though currently classified in the Q4 quartile across both Cancer Research and Cell Biology categories, the journal aspires to enhance its impact through rigorous peer review and high-quality publication. Positioned to cover the years from 2021 to 2024, it seeks to bridge gaps in foundational knowledge and promote collaborative research efforts that could pivot the current understanding of cancer metastasis. Researchers are encouraged to take advantage of this platform to advocate for advancements in cancer biology, making significant contributions that can influence both academic and clinical practices.

JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, published by Oxford University Press Inc, stands as a pivotal resource for advancing research and knowledge in the domains of neuropathology and experimental neurology. Established in 1942, this esteemed journal has expanded its influence, as evidenced by its Q1 rankings in both Neurology (clinical) and Pathology and Forensic Medicine, along with its strong placement in Cellular and Molecular Neuroscience. With an emphasis on innovative research and clinical practices, it caters to a diverse audience, including researchers and clinicians dedicated to understanding neurological disorders through a multidisciplinary lens. While not open access, this journal provides access to cutting-edge studies that are pivotal in shaping the future of medical science and pathology. Researchers benefit from its rigorous peer-review process, ensuring the publication of high-caliber work that meets the evolving demands of the field.

NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY is a premier journal dedicated to advancing the understanding of the intricate relationships between pathology and neurobiology. Published by Wiley since 1975, this journal has established itself as a crucial resource for researchers, clinicians, and students interested in the latest insights and developments in the fields of pathology, neurology, and neuroscience. With an impressive history of convergence extending to 2024, it boasts a Q1 ranking in multiple categories including Histology, Neurology, and Pathology, reflecting its high impact and reputation in the academic community. Additionally, it ranks 18th out of 208 in Pathology and Forensic Medicine with a remarkable 91st percentile, signifying its relevance and influence in medical research. While not open access, this journal provides valuable content that contributes significantly to the ongoing discourse in neurobiological advancements and is a vital reference for those engaged in this dynamic field.

Pediatric Hematology and Oncology, published by Taylor & Francis Inc, serves as a vital platform dedicated to the fields of hematology, oncology, and pediatrics, providing a comprehensive avenue for the dissemination of scholarly research and clinical advancements. With an ISSN of 0888-0018 and an E-ISSN of 1521-0669, this journal has successfully converged its expertise over the years from 1984 to 2024. Ranked in the Q3 category for Hematology and Oncology, alongside a Q2 ranking in Pediatrics, Perinatology, and Child Health (2023), it engages a diverse readership comprising researchers, healthcare professionals, and students eager to explore groundbreaking studies in child health and treatment methodologies. While it currently does not offer Open Access options, the journal is widely cited and recognized, particularly in its specialized fields, fostering a rich environment for dialogue and innovation in the management of pediatric hematological and oncological disorders. The journal is based in the United Kingdom at 530 Walnut Street, Ste 850, Philadelphia, PA 19106, making it an essential resource for those pursuing excellence in pediatric medical research.